| pubmed-article:12555236 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12555236 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:12555236 | lifeskim:mentions | umls-concept:C0013030 | lld:lifeskim |
| pubmed-article:12555236 | lifeskim:mentions | umls-concept:C0027849 | lld:lifeskim |
| pubmed-article:12555236 | lifeskim:mentions | umls-concept:C0205245 | lld:lifeskim |
| pubmed-article:12555236 | lifeskim:mentions | umls-concept:C1335671 | lld:lifeskim |
| pubmed-article:12555236 | lifeskim:mentions | umls-concept:C0678951 | lld:lifeskim |
| pubmed-article:12555236 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12555236 | pubmed:dateCreated | 2003-1-29 | lld:pubmed |
| pubmed-article:12555236 | pubmed:abstractText | Our previous study has suggested that the TaqI A polymorphism of dopamine D2 receptor gene (DRD2) is associated with the predisposition to neuroleptic malignant syndrome (NMS). However, the specificity of this polymorphism as a predictor of NMS dose not seem to be sufficient enough. Meanwhile, it has been shown that the non-carriers of Del allele of the -141C Ins/Del polymorphism in the promoter region of DRD2 have lower dopamine D2 receptor in the brain than the carriers. In addition, dopamine D3 receptor gene has a Ser(9)Gly polymorphism, which may alter the receptor function. The present study examined the association between these three polymorphisms and the development of NMS to investigate if a combination of these polymorphisms could increase the specificity as markers for NMS. The subjects were 17 psychiatric patients who had developed NMS (13 patients with schizophrenia, 3 with major depression, and 1 with dementia of the Alzheimer's type) and 163 schizophrenic patients who had never developed this syndrome. The frequency of the A1 allele was significantly (P = 0.012) higher in the patients who had developed NMS (59%) than in the patients who had not (35%). The proportion of the A1 carriers was significantly (P = 0.003) higher in the patients with NMS (16/17: 94%) than in those without the syndrome (93/163: 57%). However, no significant differences were found in the allele and genotype frequencies of the other two polymorphisms between the two groups. The present study suggests that only the TaqI A polymorphism is at least partly useful as a predictor of NMS, but the -141 C Ins/Del and Ser(9)Gly polymorphisms are not. | lld:pubmed |
| pubmed-article:12555236 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12555236 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12555236 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12555236 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12555236 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12555236 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12555236 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12555236 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12555236 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12555236 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:12555236 | pubmed:issn | 1552-4841 | lld:pubmed |
| pubmed-article:12555236 | pubmed:author | pubmed-author:Yasui-Furukor... | lld:pubmed |
| pubmed-article:12555236 | pubmed:author | pubmed-author:KondoTsuyoshi... | lld:pubmed |
| pubmed-article:12555236 | pubmed:author | pubmed-author:MiharaKazuoK | lld:pubmed |
| pubmed-article:12555236 | pubmed:author | pubmed-author:OnoShingoS | lld:pubmed |
| pubmed-article:12555236 | pubmed:author | pubmed-author:KanekoSunaoS | lld:pubmed |
| pubmed-article:12555236 | pubmed:author | pubmed-author:OtaniKoichiK | lld:pubmed |
| pubmed-article:12555236 | pubmed:author | pubmed-author:SuzukiAkihito... | lld:pubmed |
| pubmed-article:12555236 | pubmed:author | pubmed-author:SanoAkiraA | lld:pubmed |
| pubmed-article:12555236 | pubmed:author | pubmed-author:KoshiroKazuko... | lld:pubmed |
| pubmed-article:12555236 | pubmed:copyrightInfo | Copyright 2003 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:12555236 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12555236 | pubmed:volume | 117B | lld:pubmed |
| pubmed-article:12555236 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12555236 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12555236 | pubmed:pagination | 57-60 | lld:pubmed |
| pubmed-article:12555236 | pubmed:dateRevised | 2008-8-29 | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:meshHeading | pubmed-meshheading:12555236... | lld:pubmed |
| pubmed-article:12555236 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12555236 | pubmed:articleTitle | Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. | lld:pubmed |
| pubmed-article:12555236 | pubmed:affiliation | Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan. | lld:pubmed |
| pubmed-article:12555236 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12555236 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:1813 | entrezgene:pubmed | pubmed-article:12555236 | lld:entrezgene |
| entrez-gene:255239 | entrezgene:pubmed | pubmed-article:12555236 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:12555236 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:12555236 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:12555236 | lld:entrezgene |
| lhgdn:association:14802 | lhgdn:found_in | pubmed-article:12555236 | lld:lhgdn |
| lhgdn:association:36396 | lhgdn:found_in | pubmed-article:12555236 | lld:lhgdn |
